Jan 10, 2023 / 04:15PM GMT
Rachel Marie Vatnsdal Olson - JPMorgan Chase & Co, Research Division - Analyst
Hi, everyone. This is Rachel Vatnsdal from the life science tools and diagnostics team. Today, I'm joined by Prahlad from the PerkinElmer team. And so as you've seen with the rest of the sessions, today will be a 20-minute presentation from Prahlad, followed by a Q&A session. We do have mic runners throughout the room. Please raise your hand if you have a question. (Operator Instructions).
So with that, Prahlad, thank you.
Prahlad R. Singh - PerkinElmer, Inc. - CEO, President & Director
Good morning, everyone, and thank you, Rachel, for the opportunity to come and share our transformation story. It's good to be back in person, as I call it at the disease [war], after 3 years. Before I begin, I wanted to attract your attention to our safe harbor statement and encourage you to visit the Investors website section for further disclosures on any forward-looking statements that are made here today.
For those of you who are new to the company and for those who
PerkinElmer Inc at JPMorgan Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot